R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 66.28
+0.49 (0.74%)
At close: Mar 5, 2026
R&G PharmaStudies Market Cap
R&G PharmaStudies has a market cap or net worth of 6.3 billion as of March 6, 2026. Its market cap has increased by 32.70% in one year.
Market Cap
6.30B
Enterprise Value
4.59B
Revenue
789.45M
Ranking
n/a
PE Ratio
41.59
Stock Price
66.28
Market Cap Chart
Since August 2, 2022, R&G PharmaStudies's market cap has increased from 5.40B to 6.30B, an increase of 16.60%. That is a compound annual growth rate of 4.37%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 6.30B | 11.15% |
| Dec 31, 2025 | 5.67B | 19.12% |
| Dec 31, 2024 | 4.76B | -23.17% |
| Dec 29, 2023 | 6.19B | 25.30% |
| Dec 30, 2022 | 4.94B | -8.52% |
| Aug 2, 2022 | 5.40B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Wuhan Keqian Biology Co.,Ltd | 7.23B |
| Jiangsu Aidea Pharmaceutical Group | 7.15B |
| Shenzhen Weiguang Biological Products | 6.57B |
| Lifecome Biochemistry | 6.23B |
| Beijing Konruns Pharmaceutical | 6.22B |
| Xiangxue Pharmaceutical | 6.22B |
| GemPharmatech | 6.05B |
| Shanghai OPM Biosciences | 5.92B |